TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06423573: A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Sponsor: Chiesi Farmaceutici S.p.A. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 170 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$3,141,600

Rescue Site Savings

+$2,079,000

Unlock Full NCT06423573 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06423573 Rescue Dossier →